Replies to post #4 on Grant Life Sciences, Inc. (fka GLIF)

[machninetwo]

In the PR

"Issuance is a validation of our original and ongoing work on cancer detection, and we can now progress more effectively and confidently toward further development and ultimate commercialization of our cervical cancer test."


"There remains an urgent need for a comparatively simple, inexpensive and sensitive blood test for the early detection of cervical cancer," Ahlin stated. "We at Grant Life Sciences are proud and excited that we have been moving progressively toward meeting that need."


For over 50 years, the Pap smear has been the most widely used method for screening for cervical cancer, but it has proven consistently inadequate for detecting the disease in its early, most curable stages.


This will re-place Pap smears.....

Peace